IPN Therapy for Peritoneal Dialysis Patients: How It Works and Who Qualifies

June 25, 2026

Malnutrition is a serious and common complication in patients on peritoneal dialysis (PD). Unlike hemodialysis, where IDPN can be delivered through the dialysis circuit, peritoneal dialysis patients require a different nutritional intervention, one that works with their existing PD routine rather than requiring additional IV access.


Intraperitoneal nutrition (IPN) fills that role. Pharmko provides individually compounded IPN solutions to patients on peritoneal dialysis across 22+ states, working directly with nephrology teams and renal dietitians to evaluate eligibility and coordinate delivery.


What Is Intraperitoneal Nutrition?


IPN is a specialized amino acid solution that is added to, or substituted for, one or more standard peritoneal dialysis exchanges per day. Instead of using a standard dextrose-based dialysate, the patient instills an amino acid-enriched solution into the peritoneal cavity, where it dwells for the prescribed time before draining.


During the dwell, amino acids are absorbed directly across the peritoneal membrane into the systemic circulation, bypassing the GI tract entirely. This makes IPN particularly valuable for patients with concurrent GI dysfunction, poor appetite, or protein malabsorption that limits the effectiveness of oral or enteral nutritional support.


IPN is compatible with both continuous ambulatory peritoneal dialysis (CAPD) and continuous cycling peritoneal dialysis (CCPD). It requires no additional needle sticks, no IV access, and no changes to the patient's existing PD schedule, the amino acid solution simply replaces one standard exchange.


Why Peritoneal Dialysis Patients Are at Nutritional Risk


Patients with end-stage renal disease (ESRD) on peritoneal dialysis lose an average of 5 to 15 grams of protein per day through the peritoneal membrane during each dialysis exchange. This ongoing, unavoidable protein loss occurs even when patients follow their prescribed diets carefully. Over time, cumulative protein loss leads to:


  • Declining serum albumin and pre-albumin, key markers of nutritional status and mortality risk
  • Muscle wasting and progressive loss of lean body mass
  • Reduced immune function and increased susceptibility to peritonitis and other infections
  • Poor wound healing, fatigue, and reduced quality of life
  • Higher rates of hospitalization and all-cause mortality


Standard dietary counseling and oral nutritional supplementation often fail to fully compensate for these losses, particularly in patients with uremia-related anorexia or gastrointestinal symptoms. IPN provides direct amino acid repletion that bypasses the barriers to oral absorption.


Who Qualifies for IPN?


IPN eligibility is based on documented protein-energy wasting or malnutrition in a patient already receiving peritoneal dialysis, where conventional nutritional interventions have been insufficient. Clinical criteria typically include:


  • Serum albumin below 3.5 g/dL or pre-albumin below 30 mg/dL
  • Documented inadequate protein intake despite dietary counseling
  • Failure to respond to oral nutritional supplementation after a defined trial
  • Adequate peritoneal transport characteristics to support amino acid absorption
  • Absence of contraindications to peritoneal amino acid infusion (e.g., active peritonitis)


The nephrologist and renal dietitian determine eligibility in collaboration with Pharmko's clinical team. For a parallel review of nutritional support in hemodialysis patients, see our guide on malnutrition in hemodialysis patients and IDPN.


IPN vs IDPN: Key Differences


Both IPN and IDPN address malnutrition in dialysis patients, but they serve different patient populations and are delivered through entirely different routes:


  • IDPN is for hemodialysis patients, delivered IV through the dialysis blood circuit during hemodialysis sessions
  • IPN is for peritoneal dialysis patients, delivered intraperitoneally, substituting one PD exchange per day
  • IDPN provides amino acids, dextrose, and lipids; IPN provides amino acids, with dextrose from the dialysate serving the caloric function
  • Neither requires GI absorption, both bypass the gut entirely


The full spectrum of Pharmko's dialysis and renal nutrition services covers all three modalities: IDPN, IPN, and TPN.


How Pharmko Delivers IPN


Referral and clinical review


The nephrologist or renal dietitian submits a referral with supporting labs (albumin, pre-albumin, dietary history) and PD prescription details. Pharmko's clinical pharmacist reviews eligibility and works with the prescribing team to confirm the amino acid formula and exchange substitution schedule.


Compounding and delivery


Each IPN solution is individually compounded by Pharmko's pharmacy team in a USP <797> compliant sterile environment and delivered directly to the patient's home on a scheduled cycle. Solutions are cold-chain validated for stability through the planned dwell period.


Monitoring and formula adjustment


Pharmko monitors labs at regular intervals and adjusts the IPN formula in coordination with the nephrologist and dietitian, ensuring the nutritional plan remains aligned with the patient's evolving clinical status.


Contact Pharmko to refer a peritoneal dialysis patient: 1-877-540-2003


Home Infusion Therapy in New York
June 17, 2026
Pharmko is based in New York and provides home infusion therapy statewide — IV antibiotics, IVIG, TPN, IDPN, and specialty medications. Licensed, ACHC accredited, and available 24/7.
Home Infusion for Osteomyelitis
June 15, 2026
Osteomyelitis requires weeks of IV antibiotics that can often be completed at home. Learn who qualifies for OPAT, what the treatment timeline looks like, and how Pharmko supports bone infection recovery.
What Is a PICC Line
June 15, 2026
Learn what a PICC line is, how it's inserted, how to care for it at home, and why it's the most common IV access device for home infusion therapy. Pharmko nurses provide full PICC line training.
IV Iron Infusion at Home: Feraheme, Injectafer, and Iron Deficiency Anemia Treatment
June 12, 2026
Learn how IV iron infusion works at home — which products are used, who qualifies, what to expect during treatment, and how Pharmko delivers iron infusion therapy across 22+ states.
Home Infusion for Multiple Sclerosis
June 11, 2026
Learn how home infusion therapy works for multiple sclerosis, including Ocrevus and Tysabri, who qualifies for home-based MS infusions, what to expect, and how Pharmko coordinates care.
TPN at Home: Who Qualifies, How It Works, and What to Expect
June 11, 2026
Learn how total parenteral nutrition (TPN) at home works — who qualifies, how it's delivered, what daily life looks like, and how Pharmko supports patients from first dose through long-term therapy.
Low Albumin in Dialysis Patients
June 3, 2026
Low albumin is a key marker of malnutrition in dialysis patients. Learn what causes albumin decline, when IDPN is indicated, and how Pharmko supports renal nutrition across 22+ states.
Home Infusion Pump Types
June 2, 2026
Learn about the different types of infusion pumps used in home therapy, ambulatory, electronic, elastomeric, and CADD pumps, and how your pump is matched to your specific treatment.
Home Infusion for Rheumatoid Arthritis
May 30, 2026
Learn how home infusion therapy works for rheumatoid arthritis — including Remicade (infliximab) and other IV biologics, who qualifies for home treatment, and how Pharmko supports ongoing RA care.
Sterile Compounding Safety
May 26, 2026
When a patient or provider chooses a compounding pharmacy to prepare IV medications, they are trusting that the pharmacy operates under rigorous, independently enforced standards. In the United States, those standards are defined by two chapters of the United States Pharmacopeia: USP <797> for sterile compounding and USP <800> for hazardous drug handling. Pharmko operates in full compliance with both chapters. Understanding what these standards require, and what happens when they are not met, helps patients and providers make informed decisions about which pharmacy they trust with their care. What Is USP <797>? USP <797> (Pharmaceutical Compounding, Sterile Preparations) is the national standard that defines the minimum requirements for compounding sterile preparations safely. It covers: Cleanroom environment classification, ISO Class 5 at the point of compounding, ISO Class 7 for the surrounding buffer area, ISO Class 8 for the ante-room Personnel training, gowning, and aseptic technique requirements Sterilization and filtration methods by product type Beyond-use dating (BUD), how long a compounded sterile preparation remains safe to use Environmental and personnel monitoring schedules Quality assurance, documentation, and deviation management USP <797> applies to every pharmacy that prepares IV solutions, injections, eye drops, or other sterile preparations, whether they are a hospital pharmacy, ambulatory infusion center, or specialty pharmacy like Pharmko. The 2023 Revision: What Changed USP <797> was significantly revised in 2023 (effective November 2023). Key changes include: Stricter beyond-use date requirements, compounded sterile preparations must now meet more conservative dating limits unless sterility testing supports extended dating Enhanced environmental monitoring, more frequent air and surface sampling with defined action levels Clearer personnel qualification requirements, competency assessments are now required at defined intervals New category system, preparations are now categorized (Category 1 and Category 2) based on sterility assurance level and BUD Pharmacies that were compliant under the previous version of USP <797> must have updated their procedures and infrastructure to meet the 2023 revision. Pharmko updated our facilities, policies, and documentation systems in alignment with the revised chapter. What Is USP <800>? USP <800> (Pharmaceutical Compounding, Hazardous Drugs) establishes standards for the safe handling of hazardous drugs throughout the pharmacy, from receipt and storage to preparation, dispensing, and waste disposal. Hazardous drugs include certain chemotherapy agents, antiviral medications, hormones, and other drugs that pose risks of carcinogenicity, reproductive toxicity, or organ damage at low exposure levels. USP <800> requires: Negative-pressure ventilated containment primary engineering controls (C-PECs) for hazardous drug compounding Separate, dedicated hazardous drug storage areas Personal protective equipment (PPE) requirements for all staff handling hazardous drugs Closed-system drug transfer devices (CSTDs) for certain preparations Spill kits and exposure management protocols Why These Standards Matter for Patients The consequences of non-compliance are serious. High-profile compounding pharmacy failures, including a 2012 fungal meningitis outbreak linked to contaminated steroid injections that killed 64 patients and injured hundreds, demonstrated what happens when sterile compounding standards are not followed. For patients receiving home IV therapy, USP <797> compliance is not a credential to check once and forget, it reflects the ongoing daily practices of the pharmacy preparing their medications. Patients and providers should verify that any pharmacy preparing their IV solutions is accredited, state-licensed, and actively compliant with current USP standards. How Pharmko Meets These Standards Pharmko's sterile compounding facility is designed, staffed, and operated to meet USP <797> and USP <800> requirements. We are ACHC accredited, state-licensed in 22+ states, and subject to regulatory inspection. Every batch we compound is reviewed by a licensed pharmacist, and our environmental and personnel monitoring data is reviewed on a defined schedule. For a broader overview of what sterile compounding is and how it differs from retail pharmacy, see our guide on what is sterile compounding for IV therapy . For providers interested in our compounding capabilities, see our physician services page or contact our pharmacy team directly. → Contact Pharmko about sterile compounding: 1-877-540-2003
Show More